You are here

Novo Nordisk

Novo Nordisk Third-Quarter Profit Beats Analyst Estimates; Forecast Raised

Bloomberg

Wed, 10/27/10 - 09:17 am

Lilly, Novo tops among diabetes doctors

Fierce Pharma

Tue, 10/19/10 - 06:48 pm

Biosimilar threat tarnishes Novo's star status

Reuters

Tue, 10/19/10 - 11:07 am

Two Surprising Big Pharmas That Show Signs of Life

Forbes

Fri, 10/15/10 - 10:28 am

Bristol-Myers Squibb

With Meridia Gone, Can’t We Just Admit There’s No Money in Diet Drugs?

BNET Pharma

Mon, 10/11/10 - 05:55 pm

Abbott Laboratories

Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility

Mon, 10/4/10 - 03:10 pm

Levemir® FlexPen. North Carolina

drug manufacturing

Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility

Yahoo

Mon, 10/4/10 - 11:23 am

drug manufacturing

Pfizer Sues Novo Nordisk in London Court Over Patent on Insulin Device

Bloomberg

Mon, 09/27/10 - 12:24 pm

The Novo Nordisk: Hottest Big Pharma You Never Heard Of

Forbes

Fri, 09/24/10 - 11:12 am

Novo Nordisk to Double China R&D Headcount

Seeking Alpha

Wed, 09/15/10 - 09:23 am

Bristol-Myers Pays A Premium For Its Partner

Investopedia

Sat, 09/11/10 - 11:35 am

Bristol-Myers Squibb

The 15 Highest-Yielding Pharma & Biotech Stocks

Motley Fool

Thu, 09/2/10 - 09:24 am

Bristol-Myers Squibb

Abbott Laboratories

Pharmaceutical Product Development

Novo Nordisk To Test Victoza In Anti-Obesity - CEO

WSJ Online

Tue, 08/24/10 - 08:01 am

Novo Nordisk Sales Rep Loses Retaliation Lawsuit

Pharmalot

Tue, 08/10/10 - 09:52 am

sexual harassment

Novo Nordisk, Lilly, Novartis Said to Bid for Ascendis Pharma

Bloomberg Businessweek

Fri, 07/30/10 - 10:55 am

Novo's Victoza drains new scrips from rivals

Fierce Pharma

Wed, 07/28/10 - 11:15 pm

It's All About the Future for Amylin

Motley Fool

Thu, 07/22/10 - 03:49 pm

If Avandia falls, which diabetes meds fill the gap?

Fierce Pharma

Wed, 07/14/10 - 12:09 pm

Bristol-Myers Squibb

Diabetes Drug Development Pops and Drops

Motley Fool

Wed, 06/30/10 - 09:57 am

Phase 2 data for ultra-long-acting insulin degludec show the potential to effectively lower blood sugar, including when used three times a week

Pharmaceutical Processing

Sat, 06/26/10 - 10:15 am

type 1 diabetes

Pages